| Crystal Brett, LPN | |
|
10410 E 9th Ave, Spokane Valley, WA 99206-3510 | |
| (509) 321-9050 | |
| Not Available |
| Full Name | Crystal Brett |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 10410 E 9th Ave, Spokane Valley, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194407049 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | LP60462058 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Crystal Brett, LPN 10410 E 9th Ave, Spokane Valley, WA 99206-3510 Ph: (509) 321-9050 | Crystal Brett, LPN 10410 E 9th Ave, Spokane Valley, WA 99206-3510 Ph: (509) 321-9050 |
News Archive
A team of researchers from the Yale University (United States) and a Spanish company have developed a system to detect the vapours emitted by human skin in real time. The scientists think that these substances, essentially made up of fatty acids, are what attract mosquitoes and enable dogs to identify their owners.
Depression is a leading cause of disability worldwide, and treatment-resistant symptoms of depression have a terrible personal and societal cost. They can devastate lives, careers, and families. Some severely ill patients may be unable to attend to even the basic elements of self-care, while others attempt or complete suicide.
The Journal of Clinical Investigation recently published "Viewpoint" articles by Johns Hopkins University School of Medicine professors who warn that global climate change is likely to unlock dangerous new microbes, as well as threaten humans' ability to regulate body temperature.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
› Verified 6 days ago
Deborah Renee Olsen, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 11406 E Fairview Ave, Spokane Valley, WA 99206 Phone: 509-926-1031 | |
Louis Sekut, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3507 N Dick Rd, Spokane Valley, WA 99212 Phone: 509-342-4343 | |
Tara L Eggart, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 112 N University Rd Ste 102, Spokane Valley, WA 99206 Phone: 509-552-6292 | |
Kara E D'evelyn, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 11406 E Fairview Ave, Spokane Valley, WA 99206 Phone: 509-926-1031 | |
Paul James Hammerschmidt, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 5600 E. 8th Avenue, Spokane Valley, WA 99212 Phone: 509-533-6910 Fax: 509-795-8395 | |
Kayla Serbantez, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 4305 E Trent Ave, Spokane Valley, WA 99212 Phone: 509-495-1207 |